- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis
- Interventions
- secukinumab, placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boise, Idaho • Cincinnati, Ohio + 1 more
- Conditions
- Juvenile Idiopathic Arthritis (JIA)
- Interventions
- Active tcVNS, Sham tcVNS
- Device
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- San Francisco, California • Orlando, Florida • Indianapolis, Indiana + 4 more
- Conditions
- Arthritis, Juvenile Rheumatoid
- Interventions
- Celecoxib, Naproxen
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 9 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Web-based coping skills training, Online disease education
- Behavioral
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 10
- States / cities
- San Francisco, California • Chicago, Illinois • Indianopolis, Indiana + 7 more
- Conditions
- Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
- Interventions
- anakinra, Placebo
- Biological · Drug
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- Not listed
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Beverly Hills, California • San Diego, California + 29 more
- Conditions
- Anterior Uveitis, Arthritis, Juvenile Idiopathic, Iritis, Immunosuppression
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- CNTO 148 (Golimumab), Placebo, Methotrexate
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more
- Conditions
- Systemic Juvenile Idiopathic Arthritis (SJIA)
- Interventions
- ACZ885 150 mg (Canakinumab)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Columbus, Ohio
- Conditions
- Rheumatic Joint Disease
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- 800 mg ibuprofen/26.6 mg famotidine
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 10 Years to 16 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 5
- States / cities
- New Orleans, Louisiana • Boston, Massachusetts • Worcester, Massachusetts + 2 more
- Conditions
- Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
- Interventions
- 40 mg MSB11022
- Drug
- Lead sponsor
- Fresenius Kabi SwissBioSim GmbH
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Salt Lake City, Utah
- Conditions
- Arthritis Juvenile Idiopathic
- Interventions
- In open-label phase: treatment with tofacitinib, In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 2 more
- Conditions
- Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
- Interventions
- methotrexate, methotrexate - etanercept - prednisolone arm
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 15
- States / cities
- Palo Alto, California • San Diego, California • San Francisco, California + 12 more
- Conditions
- Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
- Interventions
- anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation
- Drug · Procedure
- Lead sponsor
- Fairview University Medical Center
- Other
- Eligibility
- 1 Year to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Osteoporosis, Juvenile Rheumatoid Arthritis, Dermatomyositis, Polyarthritis, Systemic Lupus Erythematosis, Vasculitis, Glucocorticoid-induced Osteoporosis
- Interventions
- denosumab
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 4 Years to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- naproxen, esomeprazole
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Arthritis, Juvenile Rheumatoid, Still's Disease, Juvenile Onset
- Interventions
- tocilizumab
- Biological
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Sacroiliitis, Psoriatic Arthritis, Mixed Connective Tissue Disease, Lupus, Enteropathic Arthropathies, Systemic Sclerosis, Sjogren's Syndrome, Sicca Syndrome, Inflammatory Arthritis, Undifferentiated Connective Tissue Diseases
- Interventions
- Resource sheets, Community Resource Specialist, Nurse Navigator
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 5 Years to 85 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Arthritis, Juvenile Rheumatoid, Uveitis
- Interventions
- Chicken type II collagen
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Arthritis, Juvenile Rheumatoid
- Interventions
- Sulfasalazine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Systemic Juvenile Idiopathic Arthritis
- Interventions
- Canakinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 19 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more
- Conditions
- Arthritis, Juvenile Rheumatoid
- Interventions
- Celecoxib, nsNSAIDs
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Washington D.C., District of Columbia + 23 more